The Patent Finder
US

Compositions and Methods of Treating Retinal Disease

US 9,265,759 Term ended
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Dec 7, 2016 (Pacific Western Bank (as Successor in Interest by Merger to Square 1 Bank)).

Term ended May 26, 2026 · Medium confidence

Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,940,721), so the cap could be lower.

Filed Dec 23, 2014 as application 14/581,462 · Granted Feb 23, 2016
Base term, 20 years from filing
Today
20 years from filing
Term ended May 26, 2026
2006 2026
Clock starts
May 26, 2006
Term ended
May 26, 2026
Granted
Feb 23, 2016
base term after the term ends fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,973,025, US 8,940,721, US 9,814,701, to May 26, 2026. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts May 26, 2006, when application 11/441,848, the earliest non-provisional in its chain, was filed (this one was filed Dec 23, 2014)May 26, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,973,025, US 8,940,721, US 9,814,701)resolves to May 26, 2026, no earlier than this term, so no changeMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderMay 26, 2026Medium confidence

This family

US 7,973,025In force
Jul 2028
Jul 2028
US 8,940,721In force
no later than Jan 2027
no later than Jan 2027
US 9,265,759this patent
May 2026
May 2026
US 9,650,342Term ended
May 2026
May 2026
US 9,896,419Term ended
May 2026
May 2026
US 10,202,348Term ended
May 2026
May 2026
US 10,913,722Term ended
Jun 2026
Jun 2026
US 11,724,987Term ended
Aug 2026
Aug 2026
8 of 10 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 28, 2015
Reel 36504, frame 756
Aldexa Therapeutics, Inc.Aldeyra Therapeutics, Inc.Change of Name
Dec 28, 2015
Reel 37365, frame 630
Jordan, Thomas A.; Dowling, John E.; Chabala, John CliffordNeuron Systems, Inc.Assignment of Assignor's Interest
Dec 28, 2015
Reel 37393, frame 995
Neuron Systems, Inc.Neuron Systems, Inc.Change of Address
Dec 28, 2015
Reel 37394, frame 30
Neuron Systems, Inc.Aldexa Therapeutics, Inc.Change of Name
Dec 7, 2016
Reel 40589, frame 196
Aldeyra Therapeutics, Inc. (F/K/A Aldexa Therapeutics, Inc.)Pacific Western Bank (as Successor in Interest by Merger to Square 1 Bank)Security Interest
Dec 5, 2018
Reel 47683, frame 482
Pacific Western Bank (Successor by Merger to Square 1 Bank)Aldeyra Therapeutics, Inc. (F/K/A Aldexa Therapeutics, Inc. F/K/A Neuron Systems, Inc.)Release of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited